Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Chi-Med, AstraZeneca's savolitinib helps some Tagrisso-resistant EGFR lung cancer patients

fiercepharmaApril 02, 2019

Tag: AstraZeneca , Chi-Med , Tagrisso-resistant EGFR lung cancer

PharmaSources Customer Service